efficacy of memantine on opioid substances withdrawal symptoms

Efficacy of Add-on Memantine to clonidine on severity of opioid substances (heroin and opium) withdrawal symptoms among opium users

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090801002266N11

Enrollment

Registered

2020-03-14

Start date

2019-11-30

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid use disorder. Opioid related disorders

Interventions

Intervention 1: intervention group:patients in this groups will be receive Bupronorphine. Bupronorphine dose will be adjusted based on patients need and all of them will be stabilized on Bupronorphine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consent to participate in the study DSM-IV criteria for drug dependence Regular and daily use of opium orally, injectable or smoke

Exclusion criteria

Exclusion criteria: Non-use of psychiatric drugs and other substances other than cigarettes Taking pain medications Comorbid of major psychiatric disorders Physical illness that is a prohibition on quitting drugs.

Design outcomes

Primary

Measure	Time frame
Severity of opium withdrawal. Timepoint: first, third, 7th, 10th and 21th days. Method of measurement: Short Opioid Withdrawal Scale(SOWS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gholam Reza Kheirabadi

Esfahan University of Medical Sciences

kheirabadi@bsrc.mui.ac.ir+98 31 3222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026